Lipella Pharmaceuticals (LIPO) and Its Rivals Head-To-Head Comparison

Lipella Pharmaceuticals (NASDAQ:LIPO) is one of 1,047 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Lipella Pharmaceuticals to similar companies based on the strength of its valuation, institutional ownership, earnings, dividends, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Lipella Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Lipella Pharmaceuticals Competitors	7584	20844	48449	1189	2.55

Lipella Pharmaceuticals presently has a consensus target price of $16.00, indicating a potential upside of 563.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 73.37%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Lipella Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Lipella Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%
Lipella Pharmaceuticals Competitors	-3,620.42%	-274.38%	-33.56%

Earnings and Valuation

This table compares Lipella Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lipella Pharmaceuticals	$483,533.00	-$4.62 million	-0.57
Lipella Pharmaceuticals Competitors	$2.55 billion	$151.16 million	-5.57

Lipella Pharmaceuticals’ competitors have higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Lipella Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ competitors have a beta of 0.79, suggesting that their average share price is 21% less volatile than the S&P 500.

Summary

Lipella Pharmaceuticals beats its competitors on 8 of the 13 factors compared.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.